On the stock market since 2025, it operates in the world of health and science. It has 48 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Debt is low and cash is strong; the finances stand solid.
Clearly below the class average.
There is growth, but not at top-of-the-class tempo.
Clearly below the class average.
Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.
Business Quality: Profit power and business quality trail similar companies in the sector.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
The stock trades 57% below its peak. The market has trimmed its expectations for the company.
Over the last 3 years, sales grew about 61% a year on average.
Sales run at $13M a year. A small number, but proof the product has real buyers.
There is $149.2M in the vault; even if every debt were paid off, $147.1M would remain.
A loss of $68.9M against $13M in annual sales.
At the current pace of spending, the cash lasts about 2.2 years. After that, the company needs to find new money.
On our five-subject report card, EVMN sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: EVMN is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (36/100) says the stock isn’t cheap.